HEALTH
- Share via
Baxter Buying European Firm: The acquisition by Baxter International Inc. would create a blood-products powerhouse. Baxter’s purchase of Immuno International of Austria for about $715 million had the approval of both companies’ boards but still needs approval from European Union and U.S. regulatory authorities, they said in a joint statement. Vienna-based Immuno is a leading manufacturer of biopharmaceutical products. Merging it with Baxter’s biotechnology group would create a major provider of products and services for transfusion medicine, including biopharmaceuticals. The two companies had combined 1995 sales of $1.6 billion and employed 8,900 people. Baxter is based in Deerfield, Ill.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.